EP-1161: 3D verification of VMAT treatment plans using electronic portal imaging device  by Pashkovskaya, O. et al.
S436  2nd ESTRO Forum 2013 
 
 Our adjusted correlation factor is: 
 
 To obtain the calibrated image, the PVrI is divided by this factor, 
converted into ODrI, divided by ODbI and finally DCC is applied. 
Conclusions: This method was applied for several beam configurations 
placing EBT2 films in different phantoms. Dose planes obtained were 
compared to equivalent measures obtained with PTW 2D-ARRAY 
seven29 and to calculated data from CMS XiO TPS. PTW Verisoft was 
used to calculate Gamma2D planes and in all cases the gamma index 
(3%, 3 mm) was below 1 for at least 95% of points. There is also a good 
agreement between the absolute doses measured at different points 
of the film with measurements made with IC. Differences are less than 
3%. 
REF. (1) A. Micke, D. Lewis and X. Yu, 'Multichannel film dosimetry with 
nonuniformity correction', Med. Phys. 38(5), 2523-2534, (2011). 
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Purpose/Objective: Pre-treatment verification of radiation plans is an 
important part of the quality assurance program. None of advanced 
treatment techniques could be applied without the guarantee that the 
delivered dose is coincided with the planning dose at a level of the 
IAEA recommendations. This analysis can be performed by the means 
of the electronic portal imaging device (EPID). The method of the 3D 
dosimetric verification of the volumetric-modulated arc therapy 
(VMAT) plans based on EPID was studied. 
Materials and Methods: It was investigated about 50 radiation 
treatment plans for the SBRT patients with non-small cell lung cancer 
(NSCLC), pulmonary metastasis, prostate cancer, head-and-neck 
tumors and brain lesions, which were treated in the Centre for 
Stereotactic Radiotherapy and Radiosurgery in Novosibirsk Research 
Institute for Circulation Pathology. During a complete treatment 
simulation at the linac the portal dose images (PDI) were received for 
each patient field and compared with the planned PDIs. 3D dosimetric 
verification was performed for all patient plans calculated according 
with the volumetric-modulated arc therapy (VMAT). The procedure 
fulfilled using the IViewGT electronic portal imaging device (EPID) and 
Dosimetry Check software. The plans were verified by comparison the 
isodose lines, 2D profiles, dose volume histograms and γ-analysis. 
Results: The planned and reconstructed dose distributions showed 
good agreement for pre-treatment verification of the VMAT plans. The 
average planned and measured isocentre dose difference was 1.20% 
(range 0.07–2.56%). 3D γ-analysis revealed γmean= 0.28 for lung 
metastasis, 0.32 for lung SBRT, 0.33 for prostate, 0.33 for brain 
lesions and 0.39 for head-and-neck tumors. The passing criteria for 
the treatment plans was established for the head-and-neck tumors 
within P% = 90% (γ ≤ 1) and within P% = 95% (γ ≤ 1) for other considered 
localizations. 
Conclusions: Verification method on the base of electronic portal 
imaging device has been successfully implemented. EPID can be used 
for the high accuracy, high resolution and fast routine pre-treatment 
verification of VMAT treatment plans.  
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Purpose/Objective: The purpose of this study was to evaluate an 
absolute pre-treatment verification method for Cyberknife therapy 
with a PinPoint ionization chamber and radiochromic EBT3 films. 
Materials and Methods: The CT scan of the Easy cube Phantom was 
acquired with the clinical parameters used for Cyberknife patients; 
the PinPoint ionization chamber and radiochromic film were 
positioned in the centre of the phantom. Eight fiducial markers were 
previously inserted into the phantom for treatment set-up. A fiducial 
tracking method was used for template QA plan: the patient’s plan 
was recalculated on the Easy Cube phantom and centred in the 
sensitive volume of the Pin Point ionization chamber. The dose was 
calculated with Ray-Tracing algorithm. The radiochromic EBT3 films 
were properly calibrated with a 6 MV linear accelerator (Clinac 600, 
Varian), delivering dose from 0 Gy to 10 Gy with 12 dose points. A 
total of 137 patients were evaluated: 91 patients with the PinPoint 
chamber only and 46 patients with PinPoint chamber and radiochromic 
film.  
Absolute dose measured with the PinPoint chamber was compared 
with the mean dose calculated in the sensitive volume of the chamber 
from the treatment planning system. The radiochromic films were 
scanned using a Epson 1000XL in transmission mode, 48 bit colour and 
resolution of 72 dpi. For each patient, calculated and measured axial 
planar dose distribution was compared with the Gamma Analysis 
Method (3% dose difference and 3 mm distance to agreement criteria) 
performed by the VeriSoft Program (PTW). 
Results: The percentage differences between calculated and 
measured PinPoint absolute dose ranges from -7.2 to 9.1 with a mean 
value of 4.8±4.1, resulting to be below 5% in the 73.9% of cases. The 
percentage of patients passing the gamma analysis (90% of pixels 
exceeding a 3% and 3 mm threshold) was 84.8%. 
Conclusions: The results obtained with PinPoint measurements show a 
good agreement between calculated and measured absolute dose. 
Preliminary results obtained with radiochromic films show some 
critical aspects. Further investigations regarding the possible 
employment of a 2D-array are required in order to perform the 
comparison between calculated and measured axial planar dose 
distribution with the possibility to speed up the procedures of QA 
program. 
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Purpose/Objective: The DAVID is an optically-transparent, 
transmission-style detector composed of two sheets of Perspex 
enclosing a vented air gap. The gap contains a series of collection 
wires running in the direction of the MLC leaf movement; each wire is 
held at a potential and is aligned with an individual MLC leaf pair. The 
signal generated at each wire is proportional to the radiation fluence 
through its associated leaf pair; with additional components from 
adjacent leaf apertures, due to scatter inside the Perspex. The 
current paradigm for using the DAVID, as an in-vivo device, is to 
record a DAVID signal during the pre-treatment verification of 
treatment delivery to a phantom; should the treatment pass the 
verification, the DAVID signal will be used as a baseline to compare 
the subsequent in-vivo responses for each treatment fraction. A new 
procedure has been suggested, where the treatment is verified using 
independent checking software; if the treatment passes this test, the 
information held by the independent software is then used to 
generate a DAVID signal, which can be used as a baseline for the 
subsequent in-vivo measurements. The independent dose check and 
generation of a baseline signal for in-vivo measurements provides a 
safe system that will catch errors in the TPS, plan transfer to the 
